Seaport Therapeutics to Participate in Two Upcoming Investor Conferences

Seaport Therapeutics (Nasdaq: SPTX), a clinical-stage neuropsychiatric therapeutics company, will participate in two investor conferences in June 2026.

Rhea-AI Impact

(Moderate)

Rhea-AI Sentiment

(Positive)How Sentiment works

Sentiment and the balance of points

Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.

How Sentiment works How the balance works

Tags

conferences

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

06/01/2026 - 07:00 AM EDT

BOSTON--(BUSINESS WIRE)-- Seaport Therapeutics, Inc., (Nasdaq: SPTX) (“Seaport” or the “Company”), a clinical-stage therapeutics company that is inventing and developing novel neuropsychiatric medicines, today announced that members of its management team will participate in the following upcoming investor conferences:

Goldman Sachs 47^th Annual Global Healthcare Conference
- Fireside Chat: June 10, 2026 at 8:00 AM EDT
UBS Virtual CNS Day
- Fireside Chat: June 15, 2026 at 10:00 AM EDT

A live webcast of the Goldman Sachs fireside chat will be available on the Investors section of the Company’s website at https://investors.seaporttx.com/news-events/events. An archived replay will be available following the presentation.

Seaport will also participate in one-on-one meetings at both conferences.

About Seaport Therapeutics

Seaport Therapeutics (Nasdaq: SPTX) is a clinical-stage therapeutics company focused on inventing and developing new medicines for patients with depression, anxiety, and other debilitating neuropsychiatric disorders. Through its differentiated approach, the Company identifies clinically validated mechanisms with established efficacy and safety which had historically been limited by high first-pass metabolism, low bioavailability, and/or side effects. Seaport applies its proprietary Glyph^TM platform to overcome those limitations and invent innovative oral therapies. With an experienced team of industry leaders, Seaport has a proven track record in neuropsychiatry drug discovery and development and delivering successful business outcomes. Seaport aims to develop novel, leading treatment options that will make a significant impact for patients and their families. For more information, please visit www.seaporttx.com.